

Benzene Health Research Consortium Technical Committee

Draft Minutes

EA Conference Call – 14 Dec 2004

Participants

Michael Bird (ExxonMobil)

Rob Schnatter (1st hr; EMBSI)

Steve Bowes (ExxonMobil)

Otto Wong (1st hr; AHS)

Don Burnett (BP)

Stuart Cagen (Shell Chemical)

Mark Fitzsimmons (Steptoe & Johnson)

Jennifer Galvin (ConocoPhillips)

Bruce Jarnot (API)

Shan Tsai (Shell Chemical)

Lorraine Twerdok (API)

Administrative Items

- Conference Call conducted in accordance with API antitrust guidelines
- Russ White (ChevronTexaco) will replace Patrick Beatty on Technical Committee (TC)
- Agenda:
 - 1st hour: discuss and review the Shanghai Health (SHS) Case Control (CC) study and Exposure Assessment (EA) with Dr. Wong
 - 2nd hour: Develop TC update for Oversight Committee meeting on 12/16/04

Review of SHS CC Study with Dr. Wong

- Matching criteria for Controls was changed to in-patient population, May 2004
- In-patient Case & Control questionnaires completed within 3-4 business days
- QA review of exposure assessment summarized
- EMBSI timeline reviewed; current sub-contract expires 8/06
- Case accrual estimate: 500+ AML, 350-400 NHL through 12/06
- Dr. Wong will return to Shanghai mid-January 2005

Benzene Health Research Consortium Technical Committee

Draft Minutes

EA Conference Call – 14 Dec 2004

TC feedback for Oversight Committee (OC) meeting

- TC to initiate regular PI calls with Dr. Fu
- TC to continue regular dialog with Drs. Wong & Irons
- TC to discuss Joint Clinical Molecular Lab (JCML) operations with Dr. Irons
- TC to assist OC in developing transition plan options for JCML
- TC to consider Fudan University-JCML clinical laboratory transition meetings with Dr. Rice (Chair, Science Review Panel) & TC representatives
- TC to highlight state-of-the-art achievements to date in SHS studies
- TC exploring independent funding (e.g., ILSI or HESI) opportunities for JCML tissue bank